APLS Apellis Pharmaceuticals, Inc.

Nasdaq Pharmaceutical Preparations DE CIK: 0001492422
AI RATING
HOLD
58% Confidence

Investment Thesis

Apellis demonstrates strong revenue growth (+28.5% YoY) and maintains an excellent balance sheet with $405M cash and conservative leverage (0.22x debt/equity). However, the company exhibits negative operating cash flow (-$61M) despite positive net income, indicating poor cash conversion quality and unsustainable fundamentals that contradict earnings reports.

Strengths

  • + Strong revenue growth of 28.5% YoY indicating market traction and demand
  • + Exceptional liquidity with 3.63x current ratio and $405.2M cash reserves
  • + Conservative capital structure with low leverage (0.22x debt/equity) and strong interest coverage (9.9x)

Risks

  • ! Negative operating cash flow of -$61M despite positive net income signals poor earnings quality and working capital management issues
  • ! Extremely low returns on equity (4.5%) and assets (1.7%) indicate inefficient capital deployment
  • ! Persistent negative free cash flow at -22.8% margin is unsustainable and erodes cash reserves despite positive profitability

Key Metrics to Watch

Financial Metrics

Revenue
268.3M
Net Income
18.7M
EPS (Diluted)
$0.15
Free Cash Flow
-61.3M
Total Assets
1.1B
Cash
405.2M

Profitability Ratios

Gross Margin N/A
Operating Margin 9.9%
Net Margin 7.0%
ROE 4.5%
ROA 1.7%
FCF Margin -22.8%

Balance Sheet & Liquidity

Current Ratio
3.63x
Quick Ratio
3.16x
Debt/Equity
0.22x
Debt/Assets
61.7%
Interest Coverage
9.85x
Long-term Debt
93.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-08T09:06:34.884785 | Data as of: 2026-03-31 | Powered by Claude AI